SCHEMBL238428

SCHEMBL238428

O=C(O)c1cccc(S(=O)(=O)N2CCC(COc3ccc(C(=O)N4CCCC5CCCC=C54)cc3)CC2)c1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP4F2 P78329 1/20 0.48
CYP4A11 Q02928 1/20 0.48
MAPT P10636 3/20 0.47
IL1RN P18510 1/20 0.47
EPHX2 P34913 1/20 0.44
KMT2A Q03164 3/20 0.43
MEN1 O00255 2/20 0.43
NR1H4 Q96RI1 1/20 0.42
APEX1 P27695 1/20 0.42
AKR1C3 P42330 3/20 0.41
GAA P10253 2/20 0.41
MAPK1 P28482 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
ALDH1A1 P00352 3/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
USP5 P45974 1/20 0.40
KDM4E B2RXH2 2/20 0.39
TDP1 Q9NUW8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL238998 0.91 KMT2A (0.46) EPHX2KMT2AMEN1MAPK1SMN1; SMN2
SCHEMBL238429 0.81 MAPT (0.50) CYP4F2CYP4A11MAPTIL1RNEPHX2
SCHEMBL3456155 0.73 ALDH1A1 (0.52) MAPTKMT2AMEN1GAASMN1; SMN2
SCHEMBL238999 0.70 TDP1 (0.51) EPHX2KMT2AMEN1SMN1; SMN2ALDH1A1
SCHEMBL3917595 0.70 NPC1 (0.58) MAPTEPHX2KMT2AMEN1SMN1; SMN2
SCHEMBL3931238 0.70 MAPT (0.70) MAPTIL1RNEPHX2KMT2AMEN1
SCHEMBL27751199 0.68 CYP4F2 (0.41) CYP4F2CYP4A11MAPTIL1RNEPHX2
SCHEMBL11713864 0.68 MAPT (0.74) MAPTIL1RNEPHX2KMT2AMEN1
SCHEMBL1001486 0.67 MAPT (1.00) MAPTIL1RNKMT2AMEN1APEX1
SCHEMBL29463849 0.67 MAPT (1.00) MAPTIL1RNKMT2AMEN1APEX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100292215-A1 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS HIGH POINT PHARMACEUTICALS, LLC (US) 2010-11-18 US claimed
US-20120004209-A1 11-Beta-Hydroxysteroid Dehydrogenase Type 1 Active Compounds HIGH POINT PHARMACEUTICALS, LLC (US) 2012-01-05 US disclosed
US-8053447-B2 11β-hydroxysteroid dehydrogenase type 1 active compounds HIGH POINT PHARMACEUTICALS, LLC (US) 2011-11-08 US disclosed
US-20100292215-A1 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS HIGH POINT PHARMACEUTICALS, LLC (US) 2010-11-18 US disclosed
EP-2010479-A1 11 BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS High Point Pharmaceuticals, LLC (US) 2009-01-07 EP disclosed
WO-2007115935-A1 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS HIGH POINT PHARMACEUTICALS, LLC (US) 2007-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120004209-A1 11-Beta-Hydroxysteroid Dehydrogenase Type 1 Active Compounds HSD11B1, HSD3B1, HSD11B2 CYP4F2 204/4885CYP4A11 29/4885MAPT 3783/4885
US-20100292215-A1 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS HSD11B1, HSD3B1, HSD17B1 CYP4F2 161/4885CYP4A11 28/4885MAPT 3649/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.